Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2026)

Organogenesis Holdings' Preferred Stock Liabilities history runs 6 years deep, the most recent figure standing at $136.8 million for Q1 2026.

• In Q1 2026, Preferred Stock Liabilities rose 9.29% year-over-year to $136.8 million; the TTM figure through Mar 2026 stood at $136.8 million (up 9.29% YoY), while the FY2025 annual figure was $133.8 million, up 9.29% from the prior year.
• Preferred Stock Liabilities was $136.8 million for Q1 2026 at Organogenesis Holdings, up from $133.8 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $136.8 million in Q1 2026 to a low of $122.4 million in Q4 2024.
• Historically, Preferred Stock Liabilities has averaged $129.5 million across 3 years, with a median of $129.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Preferred Stock Liabilities grew 9.29% in 2025, then gained 9.29% in 2026.
• A 3-year view of Preferred Stock Liabilities shows it stood at $122.4 million in 2024, then climbed by 9.29% to $133.8 million in 2025, then rose by 2.24% to $136.8 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $136.8 million (Q1 2026), $133.8 million (Q4 2025), and $130.9 million (Q3 2025), per Business Quant data.